 |
|
|
|
|
Project partners
|
The project consortium consists of 25 partners from 12 countries and more than
200 researchers are currently working on the project.
Successful
development of protein kinase inhibitors requires a multidisciplinary approach.
The consortium includes academic groups with unique expertise in biochemistry,
structural crystallography, synthetic organic chemistry, lead structure
optimisation and other fields of rational drug discovery.
|
University of Helsinki
Faculty of Pharmacy
Division of Pharmacology and Toxicology and
Viikki Drug Discovery Technology Center (DDTC)
Prof. Raimo K. Tuominen (project coordinator)
Prof. Jari
Yli-Kauhaluoma
and
Faculty of Agriculture and Forestry, Department of Applied Chemistry and
Microbiology
Prof. Kaarina
Sivonen
Prof. Annele Hatakka
Helsinki, Finland
|
CNRS
Lyon
Méthodologies de Synthèse
et Molécules Bioactives,
Université Claude Bernard Lyon 1
Prof. Peter
Goekjian
Prof. Hélène
Parrot-Lopez
Prof. Benoît Joseph
Prof. Olivier Piva
Dr. Philippe Belmont
and
Université Blaise Pascal - Clermont-Ferrand II
Prof.
Michelle Prudhomme
France
|
The Hebrew University of Jerusalem
- Hadassah Medical School
Prof. Charles L. Jaffe
Prof. Alexander Levitzki
Jerusalem, Israel
|
Ludwig Maximilians University Munich
Department of Pharmacy
Prof. Angelika Vollmar
Dr. Stefan Zahler
München, Germany
|
Université
de Genève
Laboratoire de Pharmacognosie et de Phytochimie
Section des Sciences Pharmaceutiques
Prof. Andrew
Marston
Geneva, Switzerland
|
Université de Genève
Laboratoire de chimie thérapeutique
Section de pharmacie
Prof. Leonardo
Scapozza
Geneva, Switzerland |
University of Dundee
School of Life Sciences
Prof. Sir Philip Cohen
Scotland, UK
|
University of Birmingham
Department of Immunology
Prof. Janet M. Lord
Birmingham, UK
|
University of Debrecen
Medical and Health Science Center
Department of Biophysics and Cell Biology
Prof. János Szöllõsi
Prof. György Vereb
Debrecen, Hungary
|
University of Milano-Bicocca
Professor of Internal Medicine
Prof. Carlo
Gambacorti-Passerini
Monza, Italy
|
University of Innsbruck
Institute of Pharmacy
Prof. Thierry Langer
Innsbruck, Austria
|
KTB
Tumorforschungs GmbH
ProQinase
Dr. Michael Kubbutat
Freiburg, Germany
|
CR-UK London Research Institute
Prof. Peter J. Parker
Dr. Neil Mcdonald
London, UK
|
CNRS Roscoff, Station Biologique
Prof. Laurent Meijer
Roscoff,
France
|
C3Biotech
Dr. Paul Pechan
Otterfing, Germany
|
Neurokin S.A.R.L.
Dr. Serge Timsit
Dr.
Benedicte Menn
Marseilles, France
|
Venetian Institute for Molecular Medicine (VIMM)
and University of Padova,
Departments of Biological Chemistry
and Organic Chemistry
Prof. Lorenzo A. Pinna
Prof. Giuseppe Zanotti
Padova, Italy
|
University of Oxford
Department of Biochemistry
Prof. Dame Louise Johnson
Dr. Aude Echalier
Dr. Jane A. Endicott
Dr. James McDonnell
Dr. Martin E.M. Noble
Oxford, UK
|
University of Bergen
Apoptosis Signaling Group (APSIB)
Prof. Stein-Ove Døskeland
Bergen, Norway
|
Institute of Neurobiology
of the Mediterranean Sea
(INMED / INSERM)
Dr. Yehezkel Ben-Ari
Dr. Anton Ivanov
Marseille, France
|
Inte:Ligand
Software Development Unit
Dr. Gerhard Wolber
Vienna, Austria
|
Pepscan Systems BV
Dr. Peter van Dijken
Dr. Jos Joore
Lelsyatd, The Netherlands
|
Technische Universität Braunschweig
Institut für Pharmazeutische Chemie
Prof. Conrad Kunick
Braunschweig, Germany
|
Innsbruck Medical University
Institute of Medical Chemistry and Biochemistry
Prof. Johann Hofmann
Innsbruck, Austria
|
University of Vienna
Department of Pharmacognosy
Prof. Verena M.
Dirsch, Ph.D
Vienna, Austria
|
Gause Institute of New
Antibiotics
Prof. Maria N. Preobrazhenskaya
Moscow, Russia |
Research
Center fro Biotechnology of Antibiotics
Prof. Valery Danilenko
Moscow, Russia
|
|
[ Top ]
Updated 23 July 2008
webmaster (at) proteinkinase-research.org
|